All issues online, mobile friendly. Works on mobile, tablets & desktop.

Oncopeptides’ peptide drug conjugate crossed the blood-brain barrier in the first three patients treated in a glioblastoma study at Oslo University Hospital. Drug concentrations in the tumors matched preclinical models.

Orexo’s board has resolved on a rights issue of about SEK 250 million, subject to approval at an extraordinary general meeting on November 6. The money is mainly for the company’s development programs, including the first pivotal trial of OX640.

Dutch life science investor Forbion has raised EUR 2.3 billion (USD 2.6 billion) across two new funds. This is a record for the firm and one of the largest life science venture capital raises globally in the past five years. The new money comes into a European biotech market that has long been short of growth capital.

Per Uhlén, professor of cell signaling at Karolinska Institutet, has received the 2026 Lennart Nilsson Award. The award was presented on October 8 at KI’s professorial installation ceremony in Aula Medica, in recognition of his advanced microscopy methods that visualize the fundamental processes of life.